MVX-ONCO-1, a personalized cell-based vaccine, combines inactivated autologous tumor cells and encapsulated allogeneic human cells genetically engineered to produce granulocyte–macrophage colony stimulating factor (GM-CSF). The gene discussed is CSF2; the disease is neoplasm.